Citi analyst Daniel Grosslight is opening a "Catalyst Watch" on GoodRx as he thinks there is upside to consensus numbers given the intensifying flu, RSV, and COVID season this winter. The analyst, who thinks GoodRx is likely to beat expectations in Q4 of FY22 and Q1 of FY23, has a Buy rating and $7 price target on the shares.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on GDRX: